A proof-of-concept study evaluating DLX-105 for treatment of mild to moderate plaque psoriasis
Latest Information Update: 30 May 2022
At a glance
- Drugs DLX 105 (Primary)
- Indications Plaque psoriasis
- Focus Proof of concept; Therapeutic Use
- 26 May 2022 According to an Arrivo BioVentures media release, company expects data readout in mid-2022.
- 18 Dec 2021 New trial record
- 13 Dec 2021 According to an Arrivo BioVentures media release, company expects data readout in Q2 2022.